Telo Genomics Corp.

TELO

CA87975M2085

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 09:51:36 22/05/2024 pm IST			5-day change	1st Jan Change
0.185 ^CAD	-2.63%		+8.82%	-7.50%

15/05	Telo Genomics Corp. Signs Collaboration Agreement with Emery Pharma	CI
10/04	Telo Genomics Receives Accreditation from College of American Pathologists	MT

3D Signatures Inc. Announces Resignation of Helen Stevenson as Director of the Company

August 12, 2017 at 04:05 am IST

3D Signatures Inc. announced that Helen Stevenson has resigned as a director of the Company effective immediately.

Latest news about Telo Genomics Corp.

Telo Genomics Corp. Signs Collaboration Agreement with Emery Pharma	15/05	CI
Telo Genomics Receives Accreditation from College of American Pathologists	10/04	MT
Telo Genomics Corp. Receives Accreditation from College of American Pathologists	10/04	CI
Telo Genomics' MRD Clinical Trial Expands into Multi-Center Trial; Shares up 9.5%	02/04	MT
Telo Genomics Corp. Announces Patient Recruitment for Its Minimal Respiratory Disease Clinical Trial Has Been Initiated, with Several Patient Samples Received and Processed to Date	02/04	CI
Telo Genomics Corp. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	28/02	CI
Telo Genomics Corp. Initiates MRD Clinical Trial for Multiple Myeloma Patients	13/02	CI
Telo Genomics Corp. Announces Executive Changes	09/12	CI
Telo Genomics Corp. Reports Earnings Results for the First Quarter Ended September 30, 2023	23/11	CI
Telo Genomics Corp. Announces the American Society of Hematology Accepts the Results of Teloview-Smm Technical Repeatability Validation for Presentation At Their Annual Meeting in December 10, 2023	01/11	CI
Telo Genomics Corp. Reports Earnings Results for the Full Year Ended June 30, 2023	31/23/31	CI
Telo Genomics Corp. Announces Clinical Launch of Non-Invasive Cancer Diagnostic, Teloviewsmm - an Important Commercial Milestone Achieved	17/23/17	CI
Telo Genomics Presents Positive Results in Assessing Minimal Residual Disease in Multiple Myeloma Patients at the International Myeloma Society Annual Meeting	12/23/12	CI
Telo Genomics Corp. Reports Substantial Progress Toward Clinical Launch of Teloview-SMM	29/23/29	CI
Telo Genomics Closes $2.8 Million Financing	15/23/15	MT
Telo Genomics Corp. announced that it has received CAD 2.833875 million in funding	14/23/14	CI
Telo Genomics Corp. Presents Positive Data in Newly Diagnosed Multiple Myeloma Drug Resistance Study at EHA 2023	12/23/12	CI
Telo Genomics Corp. Presents Superior Results of Its Smoldering Multiple Myeloma Studies At Asco 2023	05/23/05	CI
Telo Genomics Seeks to Raise $2 Million via Non-Brokered Private Placement	19/23/19	MT
Telo Genomics Corp. announced that it expects to receive CAD 2 million in funding	19/23/19	CI
Telo Genomics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	19/23/19	CI
Telo Genomics' Multiple Myeloma Drug Resistance Study Results Selected for Presentation At the 2023 European Hematology Congress	04/23/04	CI
Telo Genomics Corp. Advances to Final Stage of ISO Certification	15/23/15	CI
Telo Genomics Corp. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	01/23/01	CI
Telo Genomics Corp Announces Chief Executive Officer Changes	12/22/12	CI

Telo Genomics Corp. is a Canada-based biotech company. The Company is focused on the development and commercialization of predictive technological products designed to personalize treatment plans for patients who have specific conditions. The Company, through its wholly owned subsidiary, Telo Genomics Holdings Corp., is developing diagnostic and prognostic products for diseases that display genomic instability. Its lead product, TeloView SMM, is a high-complexity molecular assay available for clinical use to provide information to physicians treating patients with Smoldering Multiple Myeloma. Through proprietary telomere-based analysis, TeloView SMM selects high-risk SMM patients who are likely to benefit from earlier treatment intervention while identifying the larger subset of low-risk SMM patients who have a more stable form of the disease and do not require immediate treatment. The TeloView SMM assay has a potential total addressable market of over 500,000 tests per year.

Sector

Biotechnology & Medical Research

Calendar

29/05/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
TELO GENOMICS CORP.	-7.50%	9.65M
EXACT SCIENCES CORPORATION	-27.70%	9.87B
IOVANCE BIOTHERAPEUTICS, INC.	+27.06%	2.89B
GUARDANT HEALTH, INC.	-16.78%	2.75B
BGI GENOMICS CO., LTD.	-15.31%	2.13B
VERACYTE, INC.	-21.41%	1.65B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+68.70%	1.47B
CAREDX, INC	+29.75%	811M
SEEGENE, INC.	-5.02%	733M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-29.39%	510M